Targeted Inactivation of Mdm2 RING Finger E3 Ubiquitin Ligase Activity in the Mouse Reveals Mechanistic Insights into p53 Regulation

Cancer Cell

Volumn 12, Issue 4, 2007, Pages 355-366

  Itahana, Koji ^a   Mao, Hua ^a   Jin, Aiwen ^a   Itahana, Yoko ^a   Clegg, Hilary V ^a   Lindström, Mikael S ^a   Bhat, Krishna P ^b   Godfrey, Virginia L ^a   Evan, Gerard I ^c   Zhang, Yanping ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CELLCYCLE

Indexed keywords

PROTEIN MDM2; PROTEIN P53; UBIQUITIN PROTEIN LIGASE E3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; EMBRYO; EMBRYO DEVELOPMENT; ENZYME ACTIVITY; FEMALE; HOMOZYGOSITY; LETHALITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN INTERACTION; UBIQUITINATION;

MUS;

EID: 35148847384     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2007.09.007     Document Type: Article

References (36)

1. Christophorou M.A., Martin-Zanca D., Soucek L., Lawlor E.R., Brown-Swigart L., Verschuren E.W., and Evan G.I. Temporal dissection of p53 function in vitro and in vivo. Nat. Genet. 37 (2005) 718-726
2. Elenbaas B., Dobbelstein M., Roth J., Shenk T., and Levine A.J. The MDM2 oncoprotein binds specifically to RNA through its RING finger domain. Mol. Med. 2 (1996) 439-451
3. Francoz S., Froment P., Bogaerts S., De Clercq S., Maetens M., Doumont G., Bellefroid E., and Marine J.C. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc. Natl. Acad. Sci. USA 103 (2006) 3232-3237
4. Geyer R.K., Yu Z.K., and Maki C.G. The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat. Cell Biol. 2 (2000) 569-573
5. Grossman S.R., Perez M., Kung A.L., Joseph M., Mansur C., Xiao Z.X., Kumar S., Howley P.M., and Linvingston D.M. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol. Cell 2 (1998) 405-415
6. Haupt Y., Maya R., Kazaz A., and Oren M. Mdm2 promotes the rapid degradation of p53. Nature 387 (1997) 296-299
7. Honda R., Tanaka H., and Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420 (1997) 25-27
8. Honda R., and Yasuda H. Activity of MDM2, a ubiquitin ligase, toward or itself is dependent on the RING finger domain of the ligase. Oncogene 19 (2000) 1473-1476
9. Itahana K., Bhat K.P., Jin A., Itahana Y., Hawke D., Kobayashi R., and Zhang Y. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol. Cell 12 (2003) 1151-1164
10. Jackson M.W., and Berberich S.J. MdmX protects p53 from Mdm2-mediated degradation. Mol. Cell. Biol. 20 (2000) 1001-1007
11. Jones S.N., Roe A.E., Donehower L.A., and Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378 (1995) 206-208
12. Kawai H., Wiederschain D., and Yuan Z.M. Critical contribution of the MDM2 acidic domain to p53 ubiquitination. Mol. Cell. Biol. 23 (2003) 4939-4947
13. Ko L.J., and Prives C. p53: Puzzle and paradigm. Genes Dev. 10 (1996) 1054-1072
14. Kostic M., Matt T., Martinez-Yamout M.A., Dyson H.J., and Wright P.E. Solution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53. J. Mol. Biol. 363 (2006) 433-450
15. Kubbutat M.H.G., Jones S.N., and Vousden K.H. Regulation of p53 stability by Mdm2. Nature 387 (1997) 299-303
16. Leach F.S., Tokino T., Meltzer P., Burrell M., Oliner J.D., Smith S., Hill D.E., Sidransky D., Kinzler K.W., and Vogelstein B. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 53 (1993) 2231-2234
17. Lin J., Chen J., and Levine A.J. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to MDM-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 8 (1994) 1235-1246
18. Linares L.K., Kiernan R., Triboulet R., Chable-Bessia C., Latreille D., Cuvier O., Lacroix M., Le Cam L., Coux O., and Benkirane M. Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2. Nat. Cell Biol. 9 (2007) 331-338
19. Lindstrom M.S., Jin A., Deisenroth C., White Wolf G., and Zhang Y. Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation. Mol. Cell. Biol. 27 (2007) 1056-1068
20. Lohrum M.A.E., Ashcroft M., Kubbutat M.H.G., and Vousden K.H. Identification of a cryptic nucleolar-localization signal in MDM2. Nat. Cell Biol. 2 (2000) 179-181
21. Luna R.M., Wagner D.S., and Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378 (1995) 203-206
22. Michalovitz D., Halevy O., and Oren M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62 (1990) 671-680
23. Minsky N., and Oren M. The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression. Mol. Cell 16 (2004) 631-639
24. Momand J., Zambetti G.P., Olson D.C., George D., and Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69 (1992) 1237-1245
25. Momand J., Jung D., Wilczynski S., and Niland J. The MDM2 gene amplification database. Nucleic Acids Res. 26 (1998) 3453-3459
26. Oliner J.D., Pietenpol J.A., Thiagalingam S., Gyuris J., Kinzler K.W., and Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature 362 (1993) 857-860
27. Poyurovsky M.V., Jacq X., Ma C., Karni-Schmidt O., Parker P.J., Chalfie M., Manley J.L., and Prives C. Nucleotide binding by the Mdm2 RING domain facilitates Arf-independent Mdm2 nucleolar localization. Mol. Cell 12 (2003) 875-887
28. Poyurovsky M.V., Priest C., Kentsis A., Borden K.L., Pan Z.Q., Pavletich N., and Prives C. The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity. Embo J. 26 (2007) 90-101 10.1038/sj.emboj.7601465 Published online December 14
29. Ringshausen I., O'Shea C.C., Finch A.J., Swigart L.B., and Evan G.I. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 10 (2006) 501-514
30. Sharp D.A., Kratowicz S.A., Sank M.J., and George D.L. Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J. Biol. Chem. 274 (1999) 38189-38196
31. Stad R., Ramos Y.F.M., Litle N., Grivell S., Attema J., van der Eb A.J., and Jochmsen A.G. Hdmx stabilizes Mdm2 and p53. J. Biol. Chem. 275 (2000) 28039-28044
32. Stommel J.M., and Wahl G.M. Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J. 23 (2004) 1547-1556
33. Tanimura S., Ohtsuka S., Mitsui K., Shirouzu K., Yoshimura A., and Ohtsubo M. MDM2 interacts with MDMX through their RING finger domains. FEBS Lett. 447 (1999) 5-9
34. Thut C.J., Goodrich J.A., and Tjian R. Repression of p53-mediated transcription by MDM2, a dual mechanism. Genes Dev. 11 (1997) 1974-1986
35. Toledo F., Krummel K.A., Lee C.J., Liu C.W., Rodewald L.W., Tang M., and Wahl G.M. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell 9 (2006) 273-285
36. Yang Y., Li C.C., and Weissman A.M. Regulating the p53 system through ubiquitination. Oncogene 23 (2004) 2096-2106